It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-08 23:20:31 Source:entertainmentViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Senators hire Travis Green as coach. Green leaves the Devils after serving in an interim role
You may also like
- Emily Ratajkowski leaves NOTHING to the imagination as she goes underwear
- Two in custody after armed police swarm Auckland suburb
- Cathay Pacific asks staff to take three weeks unpaid leave as coronavirus hits bottom line
- Coronavirus death toll in Italy surpasses China
- Emily Ratajkowski leaves NOTHING to the imagination as she goes underwear
- War a real threat and Europe not ready, warns Poland's PM
- Two in custody after armed police swarm Auckland suburb
- Ukraine war: Five dead and a million without power after wave of Russian strikes
- Gynaecologist who sterilised a female patient without her consent while she was undergoing a C